Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759505 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL3070126 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL3070121 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL54831 | 0.87 | CYP2C19 (0.77) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL53985 | 0.85 | CYP2C19 (0.74) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL13038589 | 0.84 | MTNR1A (0.72) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL9731350 | 0.80 | MTNR1A (0.66) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL55965 | 0.80 | MTNR1A (0.66) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL6359193 | 0.78 | MTNR1A (0.79) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 | |
| SCHEMBL23780653 | 0.77 | SIGMAR1 (1.00) | MTNR1AMTNR1BMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088057-A1 | METHODS OF TREATING PRE-TERM LABOR | The Florida State University Research Foundation, Inc. (US) | 2014-03-27 | — | — | US | claimed |
| US-8129432-B2 | Method of correcting imbalance between bone resorption and bone formation and kits and compositions therefor | CHU SAINTE-JUSTINE (CA) | 2012-03-06 | — | — | US | claimed |
| US-20100029567-A1 | METHOD OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR | CHU SAINTE-JUSTINE (CA) | 2010-02-04 | — | — | US | claimed |
| EP-2120912-A1 | METHODS OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR | Chu Sainte-justine (CA) | 2009-11-25 | — | — | EP | claimed |
| WO-2008098379-A1 | METHODS OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR | CHU SAINTE-JUSTINE (CA) | 2008-08-21 | — | — | WO | claimed |
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | claimed |
| EP-0420064-A2 | Substituted 2-amidotetralins as melatonin agonists and antagonists | NORTHWESTERN UNIVERSITY (US) | 1991-04-03 | — | — | EP | claimed |
| US-20250255928-A1 | USE OF COLLAGEN HYDROLYSATE AS AN ACTIVE INGREDIENT IN AMELIORATING SLEEP | ROUSSELOT B.V. (BE) | 2025-08-14 | — | — | US | disclosed |
| EP-4463177-B1 | USE OF COLLAGEN HYDROLYSATE AS AN ACTIVE INGREDIENT IN AMELIORATING SLEEP | ROUSSELOT BV (BE) | 2025-05-14 | — | — | EP | disclosed |
| US-20240415788-A1 | OCULAR TREATMENTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | PHOTOPHARMICS INC (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4463177-A1 | USE OF COLLAGEN HYDROLYSATE AS AN ACTIVE INGREDIENT IN AMELIORATING SLEEP | Rousselot BV (BE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024165665-A1 | USE OF COLLAGEN HYDROLYSATE AS AN ACTIVE INGREDIENT IN AMELIORATING SLEEP | ROUSSELOT BV (BE) | 2024-08-15 | — | — | WO | disclosed |
| US-12042471-B2 | Ocular treatments for neurological and neuropsychiatric disorders | PHOTOPHARMICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2009073184-A1 | COMPOSITIONS FOR INDUCING LABOR AND ASSOCIATED METHODS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009003226-A1 | TREATMENT OR PROPHYLAXIS OR NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION | CLARENCEW PTY LTD (AU) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008098379-A1 | METHODS OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR | CHU SAINTE-JUSTINE (CA) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008098379-A1 | METHODS OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR | CHU SAINTE-JUSTINE (CA) | 2008-08-21 | — | — | WO | disclosed |
| US-5151446-A | Neurological disorders or cardiovascular disorders | NORTHWESTERN UNIVERSITY (US) | 1992-09-29 | — | — | US | disclosed |
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0420064-A2 | Substituted 2-amidotetralins as melatonin agonists and antagonists | NORTHWESTERN UNIVERSITY (US) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042471-B2 | Ocular treatments for neurological and neuropsychiatric disorders | SLC18A2, SLC6A3, SLC18A3 | MTNR1A 56/4885MTNR1B 53/4885MEN1 2498/4885 |
| US-20240415788-A1 | OCULAR TREATMENTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SLC18A2, SLC6A3, SLC18A3 | MTNR1A 56/4885MTNR1B 53/4885MEN1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.